search
Back to results

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Primary Purpose

Type 2 Diabetes

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Co-administration of 50 mg sitagliptin and 500 mg metformin
sitagliptin/metformin 50 mg/500 mg tablet
Co-administration of 50 mg sitagliptin and 850 mg metformin
sitagliptin/metformin 50 mg/850 mg tablet
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes focused on measuring Type 2 Diabetes

Eligibility Criteria

18 Years - 40 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Subject is of Chinese descent
  • Subject is in good health
  • Subject is a non-smoker

Exclusion Criteria:

  • Subject has a history of stroke or chronic seizures
  • Subject has a history of cancer
  • Subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850

    2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC

    3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500

    4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC

    Arm Description

    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: Co-administration of 50 mg sitagliptin and 500 mg metformin sitagliptin/metformin 50 mg/500 mg FDC tablet sitagliptin/metformin 50 mg/850 mg FDC tablet Co-administration of 50 mg sitagliptin and 850 mg metformin

    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: sitagliptin/metformin 50 mg/500 mg FDC tablet Co-administration of 50 mg sitagliptin and 850 mg metformin Co-administration of 50 mg sitagliptin and 500mg metformin sitagliptin/metformin 50 mg/850 mg FDC tablet

    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: Co-administration of 50 mg sitagliptin and 850 mg metformin sitagliptin/metformin 50 mg/850 mg FDC tablet sitagliptin/metformin 50 mg/500 mg FDC tablet Co-administration of 50 mg sitagliptin and 500mg metformin

    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: sitagliptin/metformin 50 mg/850 mg FDC tablet Co-administration of 50 mg sitagliptin and 500 mg metformin Co-administration of 50 mg sitagliptin and 850 mg metformin sitagliptin/metformin 50 mg/500 mg FDC tablet

    Outcomes

    Primary Outcome Measures

    Area Under the Curve (AUC(0-t)) for Sitagliptin
    AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
    Cmax for Sitagliptin and Metformin
    Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.

    Secondary Outcome Measures

    Full Information

    First Posted
    March 19, 2010
    Last Updated
    July 17, 2015
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01093794
    Brief Title
    Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)
    Official Title
    A Bioequivalence Study With Two Tablet Strengths of the Final Market Image (FMI) Sitagliptin/Metformin Fixed Dose Combination (FDC) Tablet
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2010 (undefined)
    Primary Completion Date
    June 2010 (Actual)
    Study Completion Date
    June 2010 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study will test the hypothesis that the Final Market Image (FMI) sitagliptin/metformin 50 mg/500 mg and 50 mg/850 mg (Fixed Dose Combination) FDC tablet and co-administration of corresponding doses of sitagliptin and China-sourced metformin as individual tablets will be bioequivalent based on assessment of the AUC(0-t) and Cmax, for both sitagliptin and metformin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes
    Keywords
    Type 2 Diabetes

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    28 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    1. Sit + Met500 / SitMet500 FDC / SitMet850 FDC / Sit + Met850
    Arm Type
    Experimental
    Arm Description
    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: Co-administration of 50 mg sitagliptin and 500 mg metformin sitagliptin/metformin 50 mg/500 mg FDC tablet sitagliptin/metformin 50 mg/850 mg FDC tablet Co-administration of 50 mg sitagliptin and 850 mg metformin
    Arm Title
    2. SitMet500 FDC / Sit + Met850 / Sit + Met500 / SitMet850 FDC
    Arm Type
    Experimental
    Arm Description
    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: sitagliptin/metformin 50 mg/500 mg FDC tablet Co-administration of 50 mg sitagliptin and 850 mg metformin Co-administration of 50 mg sitagliptin and 500mg metformin sitagliptin/metformin 50 mg/850 mg FDC tablet
    Arm Title
    3. Sit + Met850 / SitMet850 FDC / SitMet500 FDC / Sit + Met500
    Arm Type
    Experimental
    Arm Description
    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: Co-administration of 50 mg sitagliptin and 850 mg metformin sitagliptin/metformin 50 mg/850 mg FDC tablet sitagliptin/metformin 50 mg/500 mg FDC tablet Co-administration of 50 mg sitagliptin and 500mg metformin
    Arm Title
    4. SitMet850 FDC / Sit + Met500 / Sit + Met850 / SitMet500 FDC
    Arm Type
    Experimental
    Arm Description
    Participants were administered treatment in the following sequence with a minimum 7 day washout period between treatments: sitagliptin/metformin 50 mg/850 mg FDC tablet Co-administration of 50 mg sitagliptin and 500 mg metformin Co-administration of 50 mg sitagliptin and 850 mg metformin sitagliptin/metformin 50 mg/500 mg FDC tablet
    Intervention Type
    Drug
    Intervention Name(s)
    Co-administration of 50 mg sitagliptin and 500 mg metformin
    Intervention Description
    Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
    Intervention Type
    Drug
    Intervention Name(s)
    sitagliptin/metformin 50 mg/500 mg tablet
    Intervention Description
    Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
    Intervention Type
    Drug
    Intervention Name(s)
    Co-administration of 50 mg sitagliptin and 850 mg metformin
    Intervention Description
    Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
    Intervention Type
    Drug
    Intervention Name(s)
    sitagliptin/metformin 50 mg/850 mg tablet
    Intervention Description
    Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
    Primary Outcome Measure Information:
    Title
    Area Under the Curve (AUC(0-t)) for Sitagliptin
    Description
    AUC (0-t) is the area under the curve for the plot showing plasma concentration against time from time zero to the time of the last quantifiable concentration for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
    Time Frame
    baseline through 72 hours postdose
    Title
    Cmax for Sitagliptin and Metformin
    Description
    Cmax is the peak serum concentration of a therapeutic drug after administration; and is used to determine the rate and extent of drug absorption. Cmax is reported for sitagliptin 50 mg, metformin 500 mg and metformin 850 mg.
    Time Frame
    baseline through 72 hours postdose

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    40 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Subject is of Chinese descent Subject is in good health Subject is a non-smoker Exclusion Criteria: Subject has a history of stroke or chronic seizures Subject has a history of cancer Subject has had major surgery, donated blood or participated in another investigational study within the past 4 weeks
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

    We'll reach out to this number within 24 hrs